Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 2, 1996, Pages 236-249

  Gaw, Allan ^a   Packard, Christopher J ^a   Lindsay, Grace M ^a   Murray, Elizabeth F ^a   Griffin, Bruce A ^a   Caslake, Muriel J ^a   Colquhoun, Ian ^a   Wheatley, David J ^a   Ross Lorimer, A ^a   Shepherd, James ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; bile acid sequestrant resin; VLDL turnover

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN B; CIMETIDINE; COLESTIPOL; DIPYRIDAMOLE; EYE DROPS; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NAPROXEN; PROPRANOLOL; RESIN; SIMVASTATIN; TIMOLOL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPARTMENT MODEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIPOPROTEIN METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 9044241252     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.2.236     Document Type: Article

References (49)

1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
3. Watts GF, Lewis B, Brunt JNH, Lewis ES, Colthart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
4. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
5. Grundy SM. Treatment of hypercholesterolemia by interference with bile acid metabolism. Arch Intern Med. 1972;130:638-648.
6. Glueck CJ. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. Ann Intern Med. 1982;96:475-482.
7. Levy RI, Brensike JF, Epstein SF, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Battaglini JW, Moriarty DJ, Fisher ML, Fiedman L, Friedwald W, Detre KM. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI type II coronary intervention study. Circulation. 1984;69:325-337.
8. Witztum JL, Schonfeld G, Weidman SW, Giese WE, Dillingham MA. Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins. Metabolism. 1979;28:221-229.
9. Shepherd J, Packard CJ, Morgan HG, Third JLHC, Stewart JM, Lawrie TDV. The effects of cholestyramine on high density lipoprotein metabolism. Atherosclerosis. 1979;33:433-444.
10. Angelin B, Bjorkhem I, Einarsson K. Cholesterol 7α hydroxylase and bile acid synthesis in relation to triglyceride and lipoprotein metabolism. In: Fears R, Sabine JR, eds. Cholesterol 7α Hydroxylase. Boca Raton, Fla: CRC Press; 1986:167-177.
11. Weisweiler P. Simvastatin plus low-dose colestipol in the treatment of severe familial hypercholesterolemia. Curr Ther Res Clin Exp. 1988;44:802-806.
12. Leren TP, Hjermann X, Berg K, Leren P, Foss OP, Viksmoen L. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis. 1988;73:135-141.
13. Miettinen TA. Combined drug treatment of hyperlipidemia. Curr Opin Lipidol. 1990;1:39-42.
14. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
15. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study [4S]. Lancet. 1994;344:1383-1389.
17. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A. 1983;80:4124-4128.
18. Grundy SM, Vega GL, Bilheimer DW. Influence of combined therapy with mevinolin and interruption of hile acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med. 1985;103:339-343.
19. Vega GL, East C, Grundy SM. Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia: effects on kinetics of apolipoprotein B. Arteriosclerosis. 1989;9(suppl I):I-135-I-144.
20. Huff MW, Telford DE, Woodcroft K, Strong WLP. Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs. J Lipid Res. 1985;26:1175-1186.
21. Huff MW, Telford DE. Regulation of low density lipoprotein apoprotein B metabolism by lovastatin and cholestyramine in miniature pigs: effects on LDL composition and synthesis of LDL subfractions. Metabolism. 1989;38:256-264.
22. Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA. 1987;257:33-38.
23. Study Group, European Atherosclerosis Society. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J. 1988;9:571-600.
24. Lipid Research Clinics Program. Lipid and Lipoprotein Analysis: Manual of Laboratory Operations. Washington, DC: US Dept of Health, Education and Welfare; 1982. NIH publication 75-628.
25. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis. 1990;83:59-67.
26. Krauss RM. Physical heterogeneity of apolipoprotein B-containing lipoproteins. In: Lippel K, ed. Proceedings of Workshop on Lipoprotein Heterogeneity. Washington, DC: US Government Printing Office; 1987:15-21. NIH publication 87-2646.
27. Havekes LM, Knijff P, Beisiegel U, Habing J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 1987;28:455-463.
28. Packard CJ, Munro A, Lorimer AR, Gotto AM Jr, Shepherd J. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest. 1984;74:2178-2192.
29. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins, I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212-221.
30. Lindgren FT, Jensen CL, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GK, ed. Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. New York, NY: Wiley-Interscience; 1972:221-245.
31. Kane JP, Sata T, Hamilton RL, Havel RJ. Apoprotein composition of very low density lipoproteins of human serum. J Clin Invest. 1975;56:1622-1634.
32. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb. 1993;13:170-189.
33. Shepherd J, Packard CJ, Grundy SM, Yeshurun D, Gotto AM, Taunton OD. Effects of saturated and polyunsaturated fat diets on the chemical composition and metabolism of low density lipoproteins in man. J Lipid Res. 1980;21:91-99.
34. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
35. Berman M, Weiss MF. SAAM Manual. Washington, DC: US Government Printing Office; 1974. US Dept of Public Health Services publication 1703.
36. Demant T, Bedford D, Packard CJ, Shepherd J. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest. 1991;88:1490-1501.
37. Packard CJ, Shepherd J, Lindsay CM, Gaw A, Taskinen M-R. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J Clin Endocrinol Metab. 1993;76:1209-1216.
38. Packard CJ, Gaw A, Demant T, Shepherd J. Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism. J Lipid Res. 1995;36:172-187.
39. Berman M, Hall M, Levy RI, Eisenberg S, Bilheimer DW, Phair RD, Goebel RM. Metabolism of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteinemic subjects. J Lipid Res. 1978;19:38-56.
40. Gaw A, Packard CJ, Lindsay GM, Griffin BA, Caslake MJ, Lorimer AR, Shepherd J. Overproduction of small very low density lipoproteins (Sf 20-60) in primary moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res. 1995;36:158-171.
41. Witztum JL, Schonfeld G, Weidman SW. The effects of colestipol on the metabolism of very-low-density lipoproteins in man. J Lab Clin Med. 1976;88:1008-1018.
42. Thompson GR, Teng B, Sniderman AD. Kinetics of LDL subfractions. Am Heart J. 1987;113:514-517.
43. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res. 1991;32:1741-1753.
44. Chen GC, Liu W, Duchateau P, Allaart J, Hamilton RL, Mendel CM, Lau K, Hardman DA, Frost PH, Malloy MJ, Kane JP. Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). J Biol Chem. 1994;269:29121-29128.
45. Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG. Cholestyramine promotes receptor-mediated LDL catabolism. N Engl J Med. 1980;302:1219-1222.
46. Slater HR, Packard CJ, Bicker S, Shepherd J. Effects of cholestyramine on receptor-mediated plasma clearance and tissue uptake of human low density lipoproteins in the rabbit. J Biol Chem. 1980;255:10210-10213.
47. Kissebah AH, Alfari S, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism. 1981;30:856-858.
48. Stalenhoef AFH, Demacker PNM, Lutterman JA, van't Laar A. Plasma lipoproteins, apolipoproteins and triglyceride metabolism in familial hypertriglyceridemia. Arteriosclerosis. 1986;6:387-394.
49. Witztum JL, Young SG, Elam RL, Carew TE, Fisher M. Cholestyramine-induced changes in low density lipoprotein composition and metabolism, I: studies in the guinea pig. J Lipid Res. 1985;26:92-103.